Bazaar Updates
Closed · opens Mon 09:00 IST
Manage your watchlist and alerts here. Voting and comments need desktop.
Press ? for shortcuts
Report
Be the first to vote

Bambusa Therapeutics Files for IPO To Fund Eczema Drug Trials ↗

Started in 2024, Bambusa secured its lead drug candidates through its earlier acquisition of assets from a unit of BioNTech SE, the first to treat atopic dermatitis, commonly known as eczema, and the second to treat other inflammatory disorders including respiratory and allergic diseases.

From NDTV Profit

Read full story ↗

Open on desktop to take part.

0 comments

Comments are posted by users and are not reviewed by Bazaar Updates.

Open on desktop to take part.

No comments yet.